<DOC>
	<DOCNO>NCT01832597</DOCNO>
	<brief_summary>The purpose study collect evaluate clinical experience reach Italy use bendamustine alone combine rituximab treatment patient relapse refractory chronic lymphoproliferative disorder .</brief_summary>
	<brief_title>Efficacy Safety Study Bendamustine With Without Rituximab Chronic Lymphoproliferative Disorders</brief_title>
	<detailed_description>All patient meet criterion inclusion include study . A specific database create collect follow information : personal data , medical history , histology relate underlying disease , comorbidities , laboratory data , initial staging , data dosage number cycle administer , record toxicity data , clinical response main event ( relapse , progression , death , cause death ) . These data retrospectively examine order obtain information life-saving treatment .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>patient relapse refractory chronic lymphoproliferative disorder salvage treatment Bendamustine +/ Rituximab age â‰¥ 18 year previous treatment Bendamustine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>